PTIX
Protagenic Therapeutics, Inc. NASDAQ Listed Apr 27, 2021$0.36
-8.19%
vs $0.39
Mkt Cap $696.4K
52w Low $0.35
0.2% of range
52w High $4.51
50d MA $0.58
200d MA $1.30
P/E (TTM)
-0.1x
EV/EBITDA
—
P/B
—
Debt/Equity
-1.3x
ROE
114.2%
P/FCF
-0.2x
RSI (14)
35.80
ATR (14)
$0.04
Beta
0.47
50d MA
$0.58
200d MA
$1.30
Avg Volume
5.5K
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company is based in New York, New York.
149 Fifth Avenue · New York City, NY 10010 · US
Data updated apr 28, 2026 6:33pm
· Source: financialmodelingprep.com